Antoinette Renee Leatherberry
Known title: DirectorCIK: 0001834624
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| DRCT | ▲ Buy | Option Exercise | 37 | — | 6/12/2026 | View on chart |
| DRCT | ▼ Sell | Open Market | 23 | $67 | 6/12/2026 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 159 | — | 6/9/2026 | View on chart |
| DRCT | ▼ Sell | Open Market | 67 | $198 | 6/9/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,619 | — | 2/19/2026 | View on chart |
| ZTS | ▼ Sell | Other | 406 | $52K | 2/19/2026 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 90 | — | 1/24/2026 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 8,205 | — | 6/12/2025 | View on chart |
| DRCT | ▼ Sell | Open Market | 2,028 | $1K | 6/12/2025 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 16,462 | — | 6/10/2025 | View on chart |
| DRCT | ▼ Sell | Open Market | 4,009 | $2K | 6/10/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,225 | — | 2/8/2025 | View on chart |
| ZTS | ▼ Sell | Other | 308 | $53K | 2/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,236 | — | 2/6/2025 | View on chart |
| ZTS | ▼ Sell | Other | 310 | $54K | 2/6/2025 | View on chart |
| DRCT | ▼ Sell | Open Market | 7,038 | $6K | 12/18/2024 | View on chart |
| DRCT | ▲ Buy | Grant | 24,615 | $0 | 12/9/2024 | View on chart |
| DRCT | ▼ Sell | Open Market | 1,779 | $9K | 6/14/2024 | View on chart |
| DRCT | ▼ Sell | Open Market | 1,111 | $6K | 6/14/2024 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 8,205 | — | 6/12/2024 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 16,460 | — | 6/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,493 | — | 2/8/2024 | View on chart |
| ZTS | ▼ Sell | Other | 375 | $73K | 2/8/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,477 | — | 12/8/2023 | View on chart |
| ZTS | ▼ Sell | Other | 371 | $68K | 12/8/2023 | View on chart |
| DRCT | ▲ Buy | Option Exercise | 16,296 | $0 | 6/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
DRCT shows after-hours activity and tops Friday's gainers list
DRCT traded after the close on Friday, generating a volume spike and moving into a high‑beta zone. The stock also appeared among the day's top gainers, indicating increased after‑hours interest. Its RSI of 31.2 suggests it is not yet overbought, and the $2.54 support level remains a key reference point.
DRCT shows after-hours activity and tops Friday's gainers list. DRCT traded after the close on Friday, generating a volume spike and moving into a high‑beta zone. The stock also appeared among the day's top gainers, indicating increased after‑hours interest. Its RSI of 31.2 suggests it is not yet overbought, and the $2.54 support level remains a key reference point.